

## Special Issue

# Nuclear Receptors in the Etiology and Treatment of Cancer

### Message from the Guest Editors

Since the discovery of estrogen ablative therapy as a treatment model for breast cancer in the 19th century, targeting of nuclear receptors has been an effective strategy for the management of cancer. Mechanisms ranging from posttranslational modification of receptors, cross-talk with oncogenic kinases, expression of alternative receptor isoforms, and development of point mutations are only a few of the mechanisms that have been suggested to contribute to the oncogenic potential of nuclear receptors, as well as to the therapeutic failure of nuclear receptor-targeting drugs. Here, we seek to provide a platform for the dissemination of the latest findings around how nuclear receptor signaling impacts the progression of cancer, and how the understanding of these mechanisms might be exploited. We are pleased to invite you to submit your original article or review to this Special Issue of *Cancers*. We welcome your submissions on any topic relevant to nuclear receptors in cancer, including disease etiology, clinical pathology and prognosis, molecular mechanisms, drug targeting, endocrine disruption, and beyond. We look forward to receiving your contribution.

### Guest Editors

Dr. Christopher C. Williams

Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, 1 Drexel Dr, New Orleans, LA 70125, USA

Dr. Syreeta L. Tilghman

Division of Basic Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA

### Deadline for manuscript submissions

closed (1 December 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/170656](https://mdpi.com/si/170656)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)